One-way sensitivity analysis. (*) Model parameters not presented produced less than a $5,000 per quality-adjusted life-year (QALY) change when evaluated over their entire range. ABVD, doxorubicin, bleomycin, vinblastine, and dacarbazine; allo-SCT, allogeneic stem-cell transplantation; ASCT, autologous stem-cell transplantation; AVD+BV, brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine; ICER, incremental cost-effectiveness ratio; PET, positron emission tomography.